{"id":"NCT00640562","sponsor":"AstraZeneca","briefTitle":"Quetiapine Extended Release Depression Symptoms","officialTitle":"Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2008-03-21","resultsPosted":"2012-06-19","lastUpdate":"2012-06-19"},"enrollment":216,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia","Depression"],"interventions":[{"type":"DRUG","name":"Quetiapine Extended Release","otherNames":["Seroquel XR™"]},{"type":"DRUG","name":"Risperidone","otherNames":["Risperdal"]}],"arms":[{"label":"Quetiapine Extended Release","type":"EXPERIMENTAL"},{"label":"Risperidone","type":"ACTIVE_COMPARATOR"}],"summary":"Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.\n\nPLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.","primaryOutcome":{"measure":"Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score.","timeFrame":"12 week from baseline to last visit","effectByArm":[{"arm":"Seroquel XR","deltaMin":7.31,"sd":6.1},{"arm":"Risperidone","deltaMin":5.53,"sd":6.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":21,"countries":["Italy"]},"refs":{"pmids":["25356632","24681810"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":109},"commonTop":["Hyperprolactinemia","Asthenia","Somnolence","Sedation","Hypotension"]}}